Objective. Depression during pregnancy is a relatively common problem. Since little is known about the teratogenic effects of concomitant administration of fluoxetine and olanzapine during the organogenesis period, the aim of the present study was to evaluate the teratogenic effects of coadministration of fluoxetine and olanzapine on rat fetuses. Method. Forty-two pregnant rats were divided into seven groups, randomly. The first group received 0.5？mL of normal saline as the control. The second and third groups received fluoxetine at doses of 9？mg/kg and 18？mg/kg, respectively. Olanzapine was injected at 3？mg/kg and 6？mg/kg to the fourth and fifth groups, respectively. The sixth group received 9？mg/kg fluoxetine and 3？mg/kg olanzapine. Finally, the seventh group was administrated with fluoxetine and olanzapine at 18？mg/kg and 6？mg/kg, respectively. Drugs were injected intraperitoneally between day eight and day 15 of the pregnancy. On the 17th day of pregnancy, the fetuses were removed and micro-/macroscopically studied. Results. Fetuses of rats receiving high doses of these drugs showed a significant rate of cleft palate development, premature eyelid opening and torsion anomalies, compared to the control group ( ). It is concluded that these drugs can lead to teratogenicity, so their concomitant use during pregnancy should be avoided, or if necessary their doses must be decreased. 1. Introduction One of the most used antidepressant drugs is fluoxetine. This active ingredient belongs to the SSRIs (selective serotonin reuptake inhibitors) class. It increases serotonin levels in synaptic clefts and is used for treatment of depression [1]. It is also used for obsessive-compulsive disorder (OCD), a prevalent disease of enhanced anxiety that has been diagnosed in around 2% of world population. Estrogen and progesterone imbalance and its influence on cerebrospinal fluid partly explain the incidence of psychological problems including OCD during pregnancy [2, 3]. Researchers have shown that OCD can be triggered during fertility periods like menstruation, pregnancy, or postparturition times. Its rate can be decreased by early diagnosis and appropriate treatment [4]. Maina and colleagues have demonstrated the precipitating effect that pregnancy and parturition can have for OCD which leads to postparturition problems for both mother and baby [5]. Leckman and colleagues found that oxytocin secretion during pregnancy increases intracerebral pressure (ICP) and can also lead to OCD [6]. Olanzapine is an atypical antipsychotic drug for treating schizophrenia and other
References
[1]
S. H. Preskorn, R. Ross, and C. Stanga, “Selective serotonin reuptake inhibitors,” in Antidepressants: Past, Present and Future, vol. 157 of Handbook of Experimental Pharmacology, pp. 241–262, Springer, New York, NY, USA, 2004.
[2]
L. M. Arnold, “A case series of women with postpartum-onset obsessive-compulsive disorder,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 1, no. 4, pp. 103–108, 1999.
[3]
K. L. Wisner, K. S. Peindl, T. Gigliotti, and B. H. Hanusa, “Obsessions and compulsions in women with postpartum depression,” Journal of Clinical Psychiatry, vol. 60, no. 3, pp. 176–180, 1999.
[4]
K. E. Williams and L. M. Koran, “Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum,” Journal of Clinical Psychiatry, vol. 58, no. 7, pp. 330–334, 1997.
[5]
G. Maina, U. Albert, F. Bogetto, P. Vaschetto, and L. Ravizza, “Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery,” Psychiatry Research, vol. 89, no. 1, pp. 49–58, 1999.
[6]
J. F. Leckman, W. K. Goodman, W. G. North et al., “Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder: comparison with Tourette's syndrome and healthy controls,” Archives of General Psychiatry, vol. 51, no. 10, pp. 782–792, 1994.
[7]
S. L. Dubovsky, “Pharmacokinetic evaluation of olanzapine？+？fluoxetine for the treatment of bipolar depression,” Expert Opinion on Drug Metabolism and Toxicology, vol. 9, no. 2, pp. 207–214, 2013.
[8]
G. Z. Reus, H. M. Abelaira, F. R. Agostinho et al., “The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain,” Journal of Psychiatric Research, vol. 46, no. 8, pp. 1029–1035, 2012.
[9]
P. R. McElhatton, “The effects of benzodiazepine use during pregnancy and lactation,” Reproductive Toxicology, vol. 8, no. 6, pp. 461–475, 1994.
[10]
P. F. Brain, J. S. Ajarem, and V. V. Petkov, “The application of ethopharmacological techniques to behavioural teratology: preliminary investigations,” Acta Physiologica et Pharmacologica Bulgarica, vol. 12, no. 4, pp. 3–11, 1986.
[11]
R. C. Pohland, T. K. Byrd, M. Hamilton, and J. R. Koons, “Placental transfer and fetal distribution of fluoxetine in the rat,” Toxicology and Applied Pharmacology, vol. 98, no. 2, pp. 198–205, 1989.
[12]
C. V. Vorhees, K. D. Acuff-Smith, M. A. Schilling, J. E. Fisher, M. S. Moran, and J. Buelke-Sam, “A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats,” Fundamental and Applied Toxicology, vol. 23, no. 2, pp. 194–205, 1994.
[13]
T. M. Cabrera-Vera, F. Garcia, W. Pinto, and G. Battaglia, “Effect of prenatal fluoxetine (prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring,” Journal of Pharmacology and Experimental Therapeutics, vol. 280, no. 1, pp. 138–145, 1997.
[14]
R. A. Byrd and J. K. Markham, “Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits,” Fundamental and Applied Toxicology, vol. 22, no. 4, pp. 511–518, 1994.
[15]
H. Rosengarten and D. Quartermain, “Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats,” Pharmacology Biochemistry and Behavior, vol. 72, no. 3, pp. 575–579, 2002.
[16]
X. M. Li, K. W. Perry, D. T. Wong, and F. P. Bymaster, “Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum,” Psychopharmacology, vol. 136, no. 2, pp. 153–161, 1998.
[17]
M. Aravagiri, Y. Teper, and S. R. Marder, “Pharmacokinetics and tissue distribution of olanzapine in rats,” Biopharmaceutics and Drug Disposition, vol. 20, no. 8, pp. 369–377, 1999.
[18]
D. J. Goldstein, K. L. Sundell, and L. A. Corbin, “Birth outcomes in pregnant women taking fluoxetine,” The New England Journal of Medicine, vol. 336, no. 12, pp. 872–873, 1997.
[19]
T. F. Oberlander, S. Misri, C. E. Fitzgerald, X. Kostaras, D. Rurak, and W. Riggs, “Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure,” Journal of Clinical Psychiatry, vol. 65, no. 2, pp. 230–237, 2004.
[20]
A. Einarson, B. Fatoye, M. Sarkar et al., “Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study,” The American Journal of Psychiatry, vol. 158, no. 10, pp. 1728–1730, 2001.
[21]
A. Pastuszak, B. Schick-Boschetto, C. Zuber et al., “Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac),” The Journal of the American Medical Association, vol. 269, no. 17, pp. 2246–2248, 1993.
[22]
E. L. Moses-Kolko, D. Bogen, J. Perel et al., “Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications,” The Journal of the American Medical Association, vol. 293, no. 19, pp. 2372–2383, 2005.
[23]
R. C. Casper, B. E. Fleisher, J. C. Lee-Ancajas et al., “Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy,” Journal of Pediatrics, vol. 142, no. 4, pp. 402–408, 2003.
[24]
H. Cissoko, D. Swortfiguer, B. Giraudeau, A. Jonville-Béra, and E. Autret-Leca, “Neonatal outcome after exposure to selective serotonin reuptake inhibitors late in pregnancy,” Archives de Pediatrie, vol. 12, no. 7, pp. 1081–1084, 2005.
[25]
S. Gentile, “The safety of newer antidepressants in pregnancy and breastfeeding,” Drug Safety, vol. 28, no. 2, pp. 137–152, 2005.
[26]
C. D. Chambers, K. A. Johnson, L. M. Dick, R. J. Felix, and K. L. Jones, “Birth outcomes in pregnant women taking fluoxetine,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1010–1015, 1996.
[27]
L. S. Cohen, V. L. Heller, J. W. Bailey, L. Grush, J. S. Ablon, and S. M. Bouffard, “Birth outcomes following prenatal exposure to fluoxetine,” Biological Psychiatry, vol. 48, no. 10, pp. 996–1000, 2000.
[28]
A. M. Costei, E. Kozer, T. Ho, S. Ito, and G. Koren, “Perinatal outcome following third trimester exposure to paroxetine,” Archives of Pediatrics and Adolescent Medicine, vol. 156, no. 11, pp. 1129–1132, 2002.
[29]
D. J. Goldstein, “Effects of third trimester fluoxetine exposure on the newborn,” Journal of Clinical Psychopharmacology, vol. 15, no. 6, pp. 417–420, 1995.
[30]
S. Dodd and M. Berk, “Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility,” Expert Review of Neurotherapeutics, vol. 8, no. 9, pp. 1299–1306, 2008.
[31]
W. J. Burke, S. E. Hendricks, D. McArthur-Miller et al., “Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial,” Journal of Clinical Psychopharmacology, vol. 20, no. 4, pp. 423–427, 2000.
[32]
V. Pérez, D. Puigdemont, I. Gilaberte, E. Alvarez, and F. Artigas, “Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors,” Journal of Clinical Psychopharmacology, vol. 21, no. 1, pp. 36–45, 2001.
[33]
D. J. Brunswick, J. D. Amsterdam, J. Fawcett et al., “Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment,” Journal of Affective Disorders, vol. 68, no. 2-3, pp. 243–249, 2002.
[34]
H. K. Crewe, M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock, “The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes,” The British Journal of Clinical Pharmacology, vol. 34, no. 3, pp. 262–265, 1992.
[35]
J. A. Carrillo, A. G. Herráiz, S. I. Ramos, G. Gervasini, S. Vizcaíno, and J. Benítez, “Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine,” Journal of Clinical Psychopharmacology, vol. 23, no. 2, pp. 119–127, 2003.
[36]
N. Takzare, V. Nikoui, S. Ostadhadi, S. M. A. Nabavi, and A. Bakhtiarian, “Teratogenic effects of caffeine and clomipramine on rat fetus,” Tehran University Medical Journal, vol. 70, no. 6, pp. 335–339, 2012.
[37]
J. A. Carrillo and J. Benitez, “Clinically significant pharmacokinetic interactions between dietary caffeine and medications,” Clinical Pharmacokinetics, vol. 39, no. 2, pp. 127–153, 2000.
[38]
N. Takzare, A. Bakhtiarian, E. Saeedi, and V. Nekoui, “The teratogenic effects of alprazolam intake on rat fetus,” Tehran University Medical Journal, vol. 68, no. 10, pp. 578–582, 2011.
[39]
S. W. Wen, Q. Yang, P. Garner et al., “Selective serotonin reuptake inhibitors and adverse pregnancy outcomes,” The American Journal of Obstetrics and Gynecology, vol. 194, no. 4, pp. 961–966, 2006.
[40]
P. Malek-Ahmadi, “Olanzapine in pregnancy,” Annals of Pharmacotherapy, vol. 35, no. 10, pp. 1294–1295, 2001.
